Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting Septembe... ( WOODCLIFF LAKE N.J. Sept. 6 /- Pa...)

Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007

Date:9/6/2007

WOODCLIFF LAKE, N.J., Sept. 6 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today filed with the U.S. Securities and Exchange Commission its 2006 Annual Report on Form 10-K. The filing of Par's Form 10-K for 2006 had been delayed due to the work involved in restating its consolidated financial statements for certain prior periods, which were filed earlier this year. Par intends to file its Form 10-Q for the first and second quarters of 2007 at the earliest practicable date.

Fourth-Quarter and 2006 Results

For the fourth quarter ended December 31, 2006, Par reported total revenues of $183.6 million and net income of $5.0 million, or $0.15 per diluted share. This is compared with reported revenues of $98.1 million and a net loss of $35.7 million, or $1.04 per diluted share, for the same period in 2005. For the year ended December 31, 2006, Par reported record total revenues of $725.2 million and net income of $6.7 million, or $0.19 per diluted share. This is compared with reported revenues of $432.3 million and a net loss of $15.3 million, or $0.44 per diluted share, for 2005.

Fourth-quarter 2006 reported, or GAAP, results included severance costs of $5.2 million, a $3.2 million investment gain and a $1.0 million asset impairment, all of which are discussed in more detail below. Adjusting for these items, net income for the fourth quarter of 2006 was $6.9 million, or $0.20 per diluted share. By comparison, fourth-quarter 2005 reported results included a $40.0 million charge for the divestiture of FineTech Laboratories, Ltd. and a $9.2 million asset impairment charge related to Par's purchase of the new drug application (NDA) for Isoptin(R) SR. Adjusting for these items, the co
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine news :

1. South Africa Wins landmark case against pharmaceutical giants
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Setting up a new pharmaceutical industry in India
5. Medicis Pharmaceutical company enters pediatric market
6. Supply of Radiopharmaceuticals Hampered by Attacks
7. Pharmaceutical companies are targeting patients
8. FDA approves Watson Pharmaceuticals Oxytrol patch
9. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
10. Indian Pharmaceutical Industries Stops Manufacturing And Sale Of Valdecoxib
11. Pharmaceutical industries grant for R&D to be monitored

Post Your Comments:

(Date:5/20/2013)... 20, 2013 Dr. Robert Mokbel is ... trained to use the Laser Assisted New Attachment Procedure, ... patients with gum disease. LANAP may help many Fountain ... gum disease restore the jawbone support necessary to support ... of plaque and tartar in the mouth. Daily oral ...

(Date:5/20/2013)... May 20, 2013 In order to prepare ... and wellness team from DrSmartphoneMD launched an article series to ... , The series launched with the precautions that ... of the DrSmartphoneMD program are not one of the 3.5 ... that more than 90% of all skin cancer cases are ...

(Date:5/20/2013)... (PRWEB) May 20, 2013 Daily Gossip, online ... provide its readers with useful tips that can help them ... , According to the website Natural Vitiligo Treatment System ... the numerous positive reviews it has received from the persons ... until now, but Daily Gossip has interviewed some of the ...

(Date:5/20/2013)... 20, 2013 Eben Pagan's ... the public creating a frenzy among business owners ... elite business training. WealthSpringMarketing.com's Tiffany Hendricks has published ... an exclusive bonus. , "Eben Pagan is a ... training to individuals serious about success," reports Hendricks. ...

(Date:5/20/2013)... May 20, 2013 Mombo from ... national conference of the US Lactation Consultant Association (USLCA) ... including nurses, doctors and other health professionals. , ... at helping lactation professionals discover and learn about the ... of the most popular nursing pillows, which new mothers ...

Breaking Medicine News(10 mins):Health News:Fountain Valley, Ca Gum Disease Patients with Missing Teeth Can Now Receive Laser Gum Surgery from Dr. Robert Mokbel for Success with Dental Implants 2 Health News:Combat Skin Cancer In Summer Months 2 Health News:New Natural Vitiligo Treatment System That Helps People Treat Vitiligo Permanently Revealed by Daily Gossip Magazine 2 Health News:Eben Pagan's Accelerate: Review and Bonus Released By WealthSpringMarketing.com 2 Health News:Comfort & Harmony™ Exhibited mombo™ Nursing Pillow at USLCA’s First Inaugural Conference 2

[0] Fountain Valley, Ca Gum Disease Patients with Missing Teeth Can Now Receive Laser Gum Surgery from Dr. Robert Mokbel for Success with Dental Implants [0] Combat Skin Cancer In Summer Months [0] New Natural Vitiligo Treatment System That Helps People Treat Vitiligo Permanently Revealed by Daily Gossip Magazine [0] Eben Pagan's Accelerate: Review and Bonus Released By WealthSpringMarketing.com [0] Comfort & Harmony™ Exhibited mombo™ Nursing Pillow at USLCA’s First Inaugural Conference

... and ... IVUS, SAN DIEGO, Nov. 8 Volcano Corporation,(Nasdaq: ... measurement (FM) products designed to enhance the diagnosis and,treatment of ... quarter and first nine months of fiscal 2007. For ...

... Nabi ... Biologics to Biotest, BOCA RATON, Fla., ... third quarter,financial results. The company recorded a net loss of $15.9 ... which included,$7.5 million, or $0.12 per share, of expenses for unusual ...

... to Aid ... Decision-Making, MILFORD, Mass., ... Synapt(TM) HDMS,System to hasten its drug discovery efforts in the area ... C, HIV, osteoporosis, osteoarthritis, and high blood pressure.,Installed in June, the ...

... Hispanic youth report better dental health habits than their non-Hispanic ... researchers at Columbia University Mailman School of Public Health. ... the Journal of Health Care for the Poor and Underserved, ... community in America. , The study, a snapshot of more ...

... stomach-shielding drugs, patient health has suffered, researchers say , , ... Vioxx and Bextra off the market to spare patients, ... new study suggests. , Rates of gastrointestinal events serious ... cox-2 inhibitor medications were ordered off the market in ...

... have identified a way to detect neural progenitor cells ... system cells, in the living human brain using a ... The finding, supported by the National Institutes of Health ... depression, Parkinson,s disease, brain tumors, and a host of ...

Volcano Reports Record Third Quarter Revenues Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting Medivir Reshapes Drug Discovery Study of minority New York City youth finds unequal burden of poor dental health Vioxx Ban Tied to Rise in Serious GI Trouble Imaging neural progenitor cells in the living human brain

(Date:5/20/2013)... SAN DIEGO , May 20, 2013 Volcano ... and manufacturer of precision guided therapy tools designed to ... vascular disease, today announced it will highlight its efforts ... including its Fractional Flow Reserve (FFR) and iFR ® ... clinical and educational presentations and events at EuroPCR 2013 ...

(Date:5/20/2013)... Pa. , May 20, 2013 B. ... patient, clinician and environmental safety with products, services ... B.Braun will feature its innovative Outlook® 400ES and ... and barcoding capabilities at the American Association of ... at the Boston Convention ...

(Date:5/20/2013)... May 20, 2013 Landauer, Inc. (NYSE: ... environmental radiation measurement and monitoring, outsourced medical physics services ... its Board of Directors declared, at its meeting on ... $0.55 per share for the third quarter of fiscal ... 2013, to shareholders of record on June 7, 2013. ...

Breaking Medicine Technology:Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 2 Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 3 Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 4 B. Braun Committed To Improving Patient Safety 2 Landauer, Inc. Declares Regular Cash Dividend 2

[0] Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 [0] B. Braun Committed To Improving Patient Safety [0] Landauer, Inc. Declares Regular Cash Dividend

... Conn., Sept. 16 MedClean Technologies (OTC Bulletin Board: ... technology for the treatment and disposal of medical waste ... today announced it has signed a distribution agreement with ... organization with over 125 years of combined experience in ...

... Quarterly Dividend -- ABBOTT PARK, Ill., Sept. 16 ... ... ... // Results are keyed by longUrl, so we need to grab the first one. for (var r ...

Cached Medicine Technology:MedClean Technologies Signs Distribution Agreement with Trojan Energy Systems 2 MedClean Technologies Signs Distribution Agreement with Trojan Energy Systems 3 Abbott Declares 347th Consecutive Quarterly Dividend 2 Abbott Declares 347th Consecutive Quarterly Dividend 3 Abbott Declares 347th Consecutive Quarterly Dividend 4 Abbott Declares 347th Consecutive Quarterly Dividend 5 Abbott Declares 347th Consecutive Quarterly Dividend 6

MedClean Technologies Signs Distribution Agreement with Trojan Energy Systems Abbott Declares 347th Consecutive Quarterly Dividend

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

Medicine Products:

Adenosine Deaminase, Body Fluid ADAMTS13 Activity & Inhibitor (VWF Cleaving Protease)Acylcarnitine Quantitative Profile, Plasma Acycloguanosine, Urine